Regeneron upgraded to Buy from Neutral at Citigroup Citigroup upgraded it rating on Regeneron (REGN) to Buy from Neutral after its survey of retinal surgeons indicated the company's Eylea drug will beat estimates over the near and long term. Citi also believes Regeneron's pipeline is not adequately reflected in the current share price. The firm raised its price target for the stock to $390 from $342. Shares of Regeneron closed Friday up $1.43 to $329.50.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Regeneron price target raised to $373 from $349 at RBC Capital RBC Capital increased its price target on Regeneron as the firm thinks that the company's Q2 results addressed many of investors' concerns. The firm is upbeat on the company's near-term outlook and keeps an Outperform rating on the shares.